Responses
Oral Presentations
SATURDAY, 15 JUNE 2019
Osteoarthritis: Research in motion
Late breaking abstract session
LB0007 SUBCUTANEOUS TANEZUMAB FOR OSTEOARTHRITIS PAIN: A 24-WEEK PHASE 3 STUDY WITH A 24-WEEK FOLLOW UP
Compose a Response to This Article
Other responses
No responses have been published for this article.